Due to health issues, this site is no longer maintained and will be shut down shortly. |
BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. This is an ADR of a company whose stock trades outside of the U.S. as the symbol HK:6160.
$222.75 +3.04 (1.38%)
As of 03/27/2023 11:31:52 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.